ATE515577T1 - Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen - Google Patents

Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen

Info

Publication number
ATE515577T1
ATE515577T1 AT04765831T AT04765831T ATE515577T1 AT E515577 T1 ATE515577 T1 AT E515577T1 AT 04765831 T AT04765831 T AT 04765831T AT 04765831 T AT04765831 T AT 04765831T AT E515577 T1 ATE515577 T1 AT E515577T1
Authority
AT
Austria
Prior art keywords
treatment
inflammatory disease
genetic polymorphisms
effectiveness
polymorphisms associated
Prior art date
Application number
AT04765831T
Other languages
English (en)
Inventor
Susan Ide
Christian Lavedan
Karen Mccullough
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE515577T1 publication Critical patent/ATE515577T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
AT04765831T 2003-10-06 2004-10-05 Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen ATE515577T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50897103P 2003-10-06 2003-10-06
PCT/EP2004/011124 WO2005040416A1 (en) 2003-10-06 2004-10-05 Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease

Publications (1)

Publication Number Publication Date
ATE515577T1 true ATE515577T1 (de) 2011-07-15

Family

ID=34520002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765831T ATE515577T1 (de) 2003-10-06 2004-10-05 Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen

Country Status (13)

Country Link
US (1) US20070155772A1 (de)
EP (1) EP1673473B1 (de)
JP (1) JP2007507460A (de)
CN (1) CN1890384A (de)
AT (1) ATE515577T1 (de)
AU (1) AU2004283235B2 (de)
BR (1) BRPI0415302A (de)
CA (1) CA2541138A1 (de)
ES (1) ES2367566T3 (de)
MX (1) MXPA06003828A (de)
PL (1) PL1673473T3 (de)
PT (1) PT1673473E (de)
WO (1) WO2005040416A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2011308496A1 (en) 2010-10-01 2013-05-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012116081A2 (en) 2011-02-22 2012-08-30 The Procter & Gamble Company Methods for identifying cosmetic agents for skin care compositions
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013148808A1 (en) 2012-03-30 2013-10-03 The Procter & Gamble Company Method of generating a hyperpigmentation condition gene expression signature
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151669A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015527630A (ja) 2012-06-06 2015-09-17 ザ プロクター アンド ギャンブルカンパニー ヘア／頭皮ケア組成物向け化粧剤の同定システム及び方法
EP2885422B1 (de) 2012-08-15 2018-03-21 The Procter and Gamble Company Systeme, modelle und verfahren zur identifizierung und beurteilung von hautpflegemitteln zur behandlung einer reihe von hauterkrankungen
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
ES2548793B1 (es) * 2014-03-17 2016-07-07 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa Método pronóstico de enfermedades autoinmunes mediante el genotipado de variantes genéticas del péptido intestinal vasoactivo
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2017201461A1 (en) * 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075236A (en) * 1987-04-24 1991-12-24 Teijin Limited Method of detecting kawasaki disease using anti-tumor necrosis antibody
US6235723B1 (en) * 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
US20030119797A1 (en) * 2001-05-09 2003-06-26 Salah-Dine Chibout Methods for selective immunomodulation

Also Published As

Publication number Publication date
PT1673473E (pt) 2011-09-19
MXPA06003828A (es) 2006-06-14
PL1673473T3 (pl) 2011-12-30
EP1673473A1 (de) 2006-06-28
CN1890384A (zh) 2007-01-03
WO2005040416A1 (en) 2005-05-06
BRPI0415302A (pt) 2006-12-05
JP2007507460A (ja) 2007-03-29
CA2541138A1 (en) 2005-05-06
AU2004283235B2 (en) 2007-08-02
US20070155772A1 (en) 2007-07-05
ES2367566T3 (es) 2011-11-04
EP1673473B1 (de) 2011-07-06
AU2004283235A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
ATE515577T1 (de) Verwendung von mit der wirksamkeit der behandlung einer entzündungskrankheit assoziierten genetischen polymorphismen
Langston et al. Retinoic acid-responsive enhancers located 3 of the Hox A and Hox B homeobox gene clusters: functional analysis
ATE437962T1 (de) Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
EP2631294A3 (de) Menschliche Mikro-RNAs und Verfahren zur Hemmung davon
ATE454463T1 (de) Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien
ATE526407T1 (de) Insektenresistenz durch inhibierung von genexpression
EP1490489A4 (de) Verfahren und mittel zur überwachung und modulation des gen-silencing
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
DK1546174T3 (da) Fremgangsmåder og sammensætninger til RNA-interferens
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
WO2005087953A3 (en) Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
WO2007085497A8 (en) Markers for the prediction of outcome of anthracycline treatment
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE309812T1 (de) Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
WO2004015087A3 (en) Eukaryotic genes involved in adult lifespan regulation
Chauhan et al. Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity
Stevens et al. Fluorescence methods for probing G-quadruplex structure in single-and double-stranded DNA
ES2536002T3 (es) Marcadores para células pre-cancerígenas y cancerígenas y el método para interferir con la proliferación celular en ellas
MX2009008788A (es) Poliformismos de serpine1 son predictivos de respuesta a administracion de proteina c activada y riesgo de muerte.
Kim et al. Efficient sequence-directed psoralen targeting using pseudocomplementary peptide nucleic acids
AU2003276872A1 (en) Methods for identifying antimicrobial compounds
ATE465248T1 (de) Humane cyclooxygenase-3 und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673473

Country of ref document: EP